BCMA
Cross-source consensus on BCMA from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Benefits
Where it comes from
Highlighted claims
- BCMA is expressed on plasma cells, including long-lived bone marrow-resident plasma cells. — Resetting autoimmune disease with CAR cell therapies
- Anti-BCMA CAR T targets the effector population that CD19-targeted therapy cannot reach. — Resetting autoimmune disease with CAR cell therapies
- Anti-BCMA CT103A has been evaluated in AQP4-IgG seropositive NMOSD and progressive multiple sclerosis. — Resetting autoimmune disease with CAR cell therapies
- A BCMA-directed mRNA cell therapy approach showed durable responses in myasthenia gravis. — Resetting autoimmune disease with CAR cell therapies